

**Claims**

1. The use of a cruciferous indole compound in the preparation of a medicament for reducing undesirable toxic side effects inherent in the anti-tumor therapy with ET-743.
2. The use of ET-743 in the preparation of a medicament for an effective treatment of a tumour by combination therapy, employing in said combination therapy ET-743 with a cruciferous indole compound.
3. The use according to claim 1 or 2, wherein the cruciferous indole compound and ET-743 form part of the same medicament.
4. The use according to claim 1 or 2, wherein the cruciferous indole compound and ET-743 form part of separate medicaments.
5. The use according to any of the preceding claim, wherein the cruciferous indole compound is indole-3-carbinol.
6. The use according to any of the preceding claim, wherein the combination therapy further employs another hepatoprotector.
7. The use according to claim 6, wherein the other hepatoprotector is dexamethasone.
8. The use according to any of the preceding claim wherein the patient has a cancer selected from sarcoma, osteosarcoma, ovarian cancer, breast cancer, NSCL carcinoma, melanoma, head and neck cancer, colorectal cancer, mesothelioma, renal cancer, endometrial cancer and lung cancer.

9. A method for reducing undesirable toxic side effects inherent in the anti-tumor therapy with ET-743 which comprises administering a cruciferous indole compound to a patient.
10. A method for an effective treatment of a tumour by combination therapy, employing in said combination therapy ET-743 with a cruciferous indole compound.
11. A method according to claim 9 or 10, wherein the cruciferous indole compound is administered to a patient who is going to be treated with ET-743.
12. The method according to claim 9 or 10, wherein the cruciferous indole compound and ET-743 form part of the same medicament.
13. The method according to claim 9 or 10, wherein the cruciferous indole compound and ET-743 form part of separate medicaments.
14. The method according to any of claims 9 to 13, wherein the cruciferous indole compound is indole-3-carbinol.
15. The method according to any of claims 9 to 14, wherein the combination therapy further employs another hepatoprotector.
16. The method according to claim 15, wherein the other hepatoprotector is dexamethasone.
17. The method according to any claims 9 to 16, wherein the patient has a cancer selected from sarcoma, osteosarcoma, ovarian cancer, breast cancer, NSCL carcinoma, melanoma, head and neck cancer,

colorectal cancer, mesothelioma, renal cancer, endometrial cancer and lung cancer.

18. A composition for the treatment of cancer, which comprises ET-743 and a cruciferous indole compound.

19. The composition according to claim 18, wherein the cruciferous indole compound is indole-3-carbinol.